Pancreatic cancer showdown: surgery first or chemo first?

NCT ID NCT06978322

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at whether giving chemotherapy before surgery (neoadjuvant chemo) helps people with resectable pancreatic cancer live longer compared to having surgery right away. Thirty patients took part. The main goal was to see which approach leads to better overall survival and cleaner surgical margins.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

chemotherapy (neoadjuvant)

What this could lead to

If chemo-first works better, it could become a new standard approach for resectable pancreatic cancer, improving survival and surgical success.

What could go wrong

This is a small, single-center trial with only 30 patients. Results may not apply broadly, and the benefit of neoadjuvant chemo is still unproven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Minia University

    Minya, Minya Governorate, 61611, Egypt